相似文献
1
The Prevalence of glucose dysregulations (GDs) in patients with β-thalassemias in different countries: A preliminary ICET-A survey.
Acta Biomed. 2021 Jul 1;92(3):e2021240. doi: 10.23750/abm.v92i3.11733.
2
[Large-scale population-based genetic screening and prenatal diagnosis for thalassemias in Zhuhai City of Guangdong Province].
Zhonghua Fu Chan Ke Za Zhi. 2012 Feb;47(2):90-5.
3
Thalassemias in South Asia: clinical lessons learnt from Bangladesh.
Orphanet J Rare Dis. 2017 May 18;12(1):93. doi: 10.1186/s13023-017-0643-z.
4
Molecular prevalence of thalassemia and hemoglobinopathies among the Lao Loum Group in the Lao People's Democratic Republic.
Int J Lab Hematol. 2019 Oct;41(5):650-656. doi: 10.1111/ijlh.13080. Epub 2019 Jul 4.
5
An ICET-A survey on occult and emerging endocrine complications in patients with β-thalassemia major: Conclusions and recommendations.
Acta Biomed. 2019 Jan 15;89(4):481-489. doi: 10.23750/abm.v89i4.7774.
6
A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience.
Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020006. doi: 10.4084/MJHID.2020.006. eCollection 2020.
7
A Number of Cases in Iran Presenting with Coinheritance of Hemoglobin-H Disease and Beta-Thalassemia Minor.
Hemoglobin. 2016 Sep;40(5):316-318. doi: 10.1080/03630269.2016.1220953. Epub 2016 Sep 22.
8
Heterogeneity and gene-geography of β-thalassemia in Georgia.
Georgian Med News. 2010 Nov(188):45-51.
9
Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong -- implications for population screening.
N Engl J Med. 1997 May 1;336(18):1298-301. doi: 10.1056/NEJM199705013361805.
10
The frequency of 14 beta-thalassemia mutations in the Arab populations.
Hemoglobin. 1995;19(6):353-60. doi: 10.3109/03630269509005827.
引用本文的文献
1
The prevalence of all stype of diabetes and pre‑diabetes in the Eastern Mediterranean countries: a meta‑analysis study.
BMC Endocr Disord. 2025 Jul 1;25(1):149. doi: 10.1186/s12902-025-01959-4.
2
Pancreatic Volume in Thalassemia: Determinants and Association with Alterations of Glucose Metabolism.
Diagnostics (Basel). 2025 Feb 26;15(5):568. doi: 10.3390/diagnostics15050568.
3
Estimation of HbA1c Levels in Transfusion-Dependent Thalassemia Patients in Comparison With Normal Healthy Individuals.
Cureus. 2024 Nov 7;16(11):e73236. doi: 10.7759/cureus.73236. eCollection 2024 Nov.
4
A retrospective study of glucose homeostasis, insulin secretion, sensitivity/resistance in non- transfusion-dependent β-thalassemia patients (NTD- β Thal): reduced β-cell secretion rather than insulin resistance seems to be the dominant defect for glucose dysregulation (GD).
Acta Biomed. 2023 Dec 5;94(6):e2023262. doi: 10.23750/abm.v94i6.15001.
5
Recent advancements in glucose dysregulation and pharmacological management of osteoporosis in transfusion-dependent thalassemia (TDT): an update of ICET-A (International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine).
Acta Biomed. 2023 Jun 14;94(3):e2023178. doi: 10.23750/abm.v94i3.14805.
6
Longitudinal study of ICET-A on glucose tolerance, insulin sensitivity and β-cell secretion in eleven β-thalassemia major patients with mild iron overload.
Acta Biomed. 2023 Feb 13;94(1):e2023011. doi: 10.23750/abm.v94i1.14000.
7
Insulin-Like Growth Factor -1 (IGF-1) and Glucose Dysregulation in Young Adult Patients with β-Thalassemia Major: Causality or Potential Link?
Acta Biomed. 2022 Dec 16;93(6):e2022331. doi: 10.23750/abm.v93i6.13288.
8
Evolution of Combined Impaired Fasting Glucose and Impaired Glucose Tolerance in β-Thalassemia Major: Results in 58 Patients with a Mean 7.7- year Follow-Up.
Acta Biomed. 2022 Jul 1;93(3):e2022242. doi: 10.23750/abm.v93i3.12825.
9
The The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network.
Acta Biomed. 2022 May 11;93(2):e2022162. doi: 10.23750/abm.v93i2.12056.
10
Screening for glucose dysregulation in β-thalassemia major (β-TM): An update of current evidences and personal experience.
Acta Biomed. 2022 Mar 14;93(1):e2022158. doi: 10.23750/abm.v93i1.12802.
本文引用的文献
1
Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis.
Biomed Res Int. 2019 Apr 18;2019:6573497. doi: 10.1155/2019/6573497. eCollection 2019.
2
Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand.
PLoS One. 2019 Mar 20;14(3):e0214148. doi: 10.1371/journal.pone.0214148. eCollection 2019.
3
Guidelines for diagnosis and management of Beta-thalassemia intermedia.
Pediatr Hematol Oncol. 2014 Oct;31(7):583-96. doi: 10.3109/08880018.2014.937884.
4
Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
Br J Haematol. 2006 Aug;134(4):438-44. doi: 10.1111/j.1365-2141.2006.06203.x. Epub 2006 Jul 4.
Zotero 插件